Regulation Without Regret: How to Navigate Health Regulations in Africa Without Killing Speed or Innovation

Hamza Asumah, MD, MBA, MPH

The Regulatory Reality Check

If you’re building a healthtech startup in Africa and regulatory approval feels like navigating a maze blindfolded, you’re not wrong. Marketing authorization in sub-Saharan Africa typically lags 4-7 years between first regulatory submission to a well-resourced agency and final approval. That’s not a bug in the system—it’s the reality of fragmented regulatory capacity across 54 countries, each with its own requirements.

But here’s what most founders miss: regulatory delays aren’t inevitable if you understand how the system actually works.

Understanding the Landscape

The African Medicines Regulatory Harmonization initiative, formalized in 2009, aims to create more effective and transparent regulatory mechanisms through collaborative regional approaches that achieve faster product approvals. Instead of 54 separate regulatory pathways, Africa is consolidating around five Regional Economic Communities that allow joint reviews.

The practical reality: After a novel medicine is approved in a high-income country like the United States, it takes an average of 4-7 years for approval in sub-Saharan African countries. For digital health tools and diagnostics, the pathway is less clear—and that’s both a curse and an opportunity.

The Approval Pathways That Actually Work

1. Reliance and Recognition Mechanisms

National regulatory authorities may rely on or recognize regulatory decisions made by a reference agency, avoiding full review of submitted data and achieving shorter overall approval timelines. South Africa’s SAHPRA, for instance, recognizes approvals from the EMA, FDA, Health Canada, MHRA, Swissmedic, TGA Australia, and MHLW Japan.

What this means for you: If your product has FDA or EMA approval, you can potentially fast-track approval in markets that recognize these decisions. Don’t file blind—lead with your strongest regulatory credential.

2. Regional Harmonization Initiatives

The East African Community has launched joint review processes that allow one submission to potentially unlock Kenya, Rwanda, Tanzania, Uganda, Burundi, and Zanzibar. Regional initiatives coordinate activities, rely on each other’s work and trusted regulatory authorities, applying principles of smart regulation.

Critical insight: Nigeria, Ghana, Tanzania operate at maturity level 3 on WHO assessment scales—meaning they have relatively robust processes. Start there if you’re building for the continent.

3. WHO Prequalification and Collaborative Registration

The WHO developed guidelines for a Collaborative Registration Procedure for WHO-prequalified products, designed to accelerate registration through improved information sharing between WHO PQP and local agencies. This pathway is particularly relevant for diagnostics and therapeutics targeting disease burdens in Africa.

The Sandbox Strategy

Here’s the uncomfortable truth: formal regulatory approval isn’t always your first gate. Many successful African healthtech companies have operated in grey zones—providing decision support tools, wellness platforms, or “non-diagnostic” services that don’t trigger full medical device regulation.

The strategy: Build, deploy at small scale, gather evidence, then pursue formal approval when you have proof of clinical utility and economic value. Several countries have piloted regulatory sandboxes, though they’re not formalized everywhere.

Engaging Early Without Freezing Your Roadmap

Pre-submission meetings matter. Most African regulatory authorities will engage informally before formal submission. Use this to:

• Understand exactly what clinical evidence they need (it’s often less than you think)
• Clarify whether your product even requires full medical device registration
• Get early feedback on your quality management system

Risk-based assessment approaches allow authorities to stratify products and apply appropriate review intensity, with reduced timelines for lower-risk products. Position your product correctly—if it’s software-only decision support, you may qualify for lighter review.

The Documentation Reality

African regulatory submissions often require:

• Certificate of Pharmaceutical Product from country of origin
• GMP certification from manufacturer
• Clinical evidence (though often accepted from other jurisdictions)
• Local representation agreement
• Registration fees ranging from $500-$15,000 depending on product class and country

The killer detail most founders miss: The use of facilitated regulatory pathways and risk-based approaches can reduce approval times from 501 calendar days to 68 calendar days.

What Success Looks Like

mPharma (Ghana/Kenya): Built pharmacy network first, then pursued diagnostic and teleconsultation services. Regulatory engagement came after product-market fit, not before.

Helium Health (Nigeria): Positioned initially as hospital management software (not a medical device), scaled to 4,000+ facilities, then added clinical decision support features incrementally.

Strategy: Don’t let regulatory uncertainty prevent you from building. Identify the regulatory-light version of your product, deploy it, gather evidence, then pursue full approval with data in hand.

The Real Risks to Manage

Regulation is serious. Concerns about poor quality, unsafe, and abandoned medical devices continue globally, with evidence suggesting these are linked to poor governance. The risk isn’t just to patients—it’s to your business.

But the bigger risk? Building a perfect product that takes 5 years to approve while your market moves on.

Tactical Recommendations

1. Start with recognition markets: Target South Africa, Kenya, or Ghana if you have FDA/EMA approval. They have reliance mechanisms.
2. Engage early, file late: Meet regulators 12-18 months before formal submission. Understand their concerns. Adjust your development roadmap accordingly.
3. Use WHO pathways when possible: If your product addresses WHO priority diseases, the prequalification route can unlock multiple markets simultaneously.
4. Don’t weaponize regulation: Some founders overindex on regulatory approval as a moat. In Africa, distribution, trust, and payment models matter more than your CE mark.
5. Build locally, certify globally: Manufacturing or assembly in-country can sometimes simplify approval and create goodwill with regulators.

The African Medicines Agency (AMA) is coming. Rather than 54 national agencies with separate requirements, the AMA intends to streamline regulatory processes and enable expedited approvals for products meeting African health needs. When it’s fully operational, the entire game changes.

Until then? Regulation is a navigation challenge, not a roadblock. The founders who win are those who engage thoughtfully, move quickly, and don’t let perfect regulatory compliance kill commercial momentum.